Trial design of a first-in-human phase 1 evaluation of SY-1365, a first-in-class selective CDK7 inhibitor, with initial expansions in ovarian and breast cancer
| Autor: | David A. Roth, Kyriakos P. Papadopoulos, Panagiotis A. Konstantinopoulos, Ursula A. Matulonis, Kristin Stephens, Rinath Jeseslsohn, Dejan Juric, Khanh T. Do, Anthony W. Tolcher, Geoffrey I. Shapiro, Graeme Hodgson, Emmanuelle DiTomaso |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Cancer Research
Class (set theory) 030505 public health business.industry First in human medicine.disease 03 medical and health sciences 0302 clinical medicine Breast cancer Oncology Cancer research Medicine 030212 general & internal medicine Cyclin-dependent kinase 7 0305 other medical science business |
| Zdroj: | Journal of Clinical Oncology. 36:TPS2600-TPS2600 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2018.36.15_suppl.tps2600 |
| Popis: | TPS2600Background: SY-1365 is a selective and potent covalent CDK7 inhibitor. CDK7 activity has been implicated in various solid tumors with transcriptional dependencies. Recent preclinical studies... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|